Yes, eating poppy seeds can trigger a positive opiate result on a urine drug screen, because raw poppy seeds retain trace morphine and codeine from the seed pod. It is not a myth and not a loophole. It is exactly why federal workplace testing programs raised the opiate cutoff from 300 ng/mL to 2000 ng/mL in 1998, a change designed to separate dietary poppy seed exposure from opioid use while still catching real positives.
For employers building or buying a drug testing program, the poppy seed question is not really about seeds. It is about picking the right cutoff, understanding what a point-of-care panel can and cannot tell you, and knowing that a non-negative screen is a screen, not a verdict.
Why poppy seeds show up on opiate tests at all
Poppy seeds come from the opium poppy plant, the same plant that produces morphine and codeine. Commercial seed processing removes most of the surface residue, but it does not remove all of it. Depending on the growing region, harvest method, and washing process, seeds sold for food use can still carry measurable morphine and codeine.
A controlled dosing study published through the National Institutes of Health's National Library of Medicine gave participants 45 gram raw poppy seed doses containing 15.7 mg of morphine and 3.1 mg of codeine per dose, an amount chosen to reflect a worst case, unprocessed exposure. At the federal urine cutoff in place at the time of the study, 2000 ng/mL, morphine remained detectable for roughly 12 hours after the second dose. At the older 300 ng/mL threshold, most participants were still positive a full 24 hours later.
That gap between thresholds is the entire story. A low cutoff catches poppy seed muffins. A higher cutoff is built to let that noise pass through while still flagging real opioid use.
The 1998 cutoff change: from 300 ng/mL to 2000 ng/mL
The Department of Health and Human Services regulates federal workplace drug testing through the Mandatory Guidelines for Federal Workplace Drug Testing Programs. In a September 1997 notice, HHS proposed raising the opiate cutoff specifically because too many screen positives were turning out to be dietary, not drug related. The proposal stated plainly that "many who have not used heroin but had taken a prescribed codeine or morphine medication or eaten poppy seeds (which may contain morphine and/or codeine) have also tested positive," and noted that 87 percent of opiate positives reported by laboratories at the time were ultimately verified as negative once a Medical Review Officer looked at them.
HHS finalized the change in a November 1998 notice, amending the initial test cutoff and the confirmatory cutoffs for morphine and codeine from 300 ng/mL to 2000 ng/mL, effective December 1, 1998. The Department of Transportation's testing program, governed by 49 CFR Part 40, uses the same 2000 ng/mL cutoff for codeine and morphine today, along with a 10 ng/mL cutoff for 6-acetylmorphine, a metabolite specific to heroin that poppy seeds do not produce. A confirmed 6-AM positive is one of the clearest ways a lab distinguishes heroin use from poppy seed exposure, because 6-AM has no dietary source.
Why employers still see both cutoffs on the market
Point-of-care opiate panels are manufactured and sold at more than one cutoff, commonly labeled OPI 300 and OPI 2000 (sometimes shown as MOP 2000 on multi-panel cups and cards). Both are legitimate configurations. The right one depends on what the program is trying to catch and what population it is testing.
A 300 ng/mL panel is more sensitive. It will flag lower concentrations of opiates, which can be useful in clinical, treatment, or corrections settings where the goal is to detect any recent opioid exposure, including lower-dose or later-window use. The tradeoff is a much higher rate of dietary false positives from poppy seed foods.
A 2000 ng/mL panel is the federal workplace standard. It is built to filter out poppy seed noise while still catching the concentrations associated with actual opioid use or abuse. For DOT-regulated safety-sensitive positions and most non-DOT workplace programs modeled on the federal guidelines, the higher cutoff is the standard choice.
OPI 300 vs. OPI 2000: cutoff comparison for program operators
| Factor | OPI 300 ng/mL panel | OPI 2000 ng/mL panel (federal standard) |
|---|---|---|
| Sensitivity to poppy seed foods | High. Ordinary poppy seed bagels, muffins, or dressings can trigger a non-negative screen. | Low. Designed specifically to filter out typical dietary poppy seed exposure. |
| Typical use case | Clinical, treatment, recovery monitoring, or corrections settings screening for any recent opioid exposure. | DOT-regulated safety-sensitive testing and most workplace pre-employment, random, and post-accident programs. |
| Regulatory alignment | Not the federal workplace standard; used where broader sensitivity is the goal. | Matches HHS Mandatory Guidelines and 49 CFR Part 40 cutoffs used in DOT testing. |
| False positive burden from diet | Meaningfully higher, driving more non-negative screens that require MRO review and confirmation. | Substantially reduced, though not eliminated entirely with heavy consumption close to collection. |
| Confirmation still required | Yes. Any non-negative screen needs lab-based GC-MS or LC-MS/MS confirmation. | Yes. Same confirmation requirement applies regardless of cutoff chosen. |
The Defense Department's 2023 poppy seed warning
In February 2023, the Department of Defense issued a memorandum to the military services warning that poppy seed consumption could produce a codeine-positive urinalysis result. The memo cited data suggesting some poppy seed varieties carry higher codeine contamination than previously understood and advised service members to avoid poppy seed products, including baked goods, out of caution ahead of testing. It is a useful reference point for civilian employers too: even a federal testing population operating under strict cutoffs and controlled conditions gets a formal advisory about this exact food.
The lesson for a workplace program is not to ban poppy seeds. It is to make sure the cutoff, the confirmation process, and the review step are all doing their jobs together, so a bagel does not end someone's employment before a lab and a Medical Review Officer ever look at the specimen.
MRO review and confirmation testing settle the disputed cases
A point-of-care opiate result, whatever the cutoff, is a screen. It is presumptive, not final. Any non-negative screen should route to laboratory confirmation using gas chromatography-mass spectrometry or liquid chromatography-tandem mass spectrometry, methods that identify and quantify the specific compounds present rather than reacting to a class of drugs.
In a reviewed program, a Medical Review Officer then examines the confirmed lab result, contacts the donor, and asks about legitimate explanations, including poppy seed consumption, prescribed medication, or other documented use, before a result is reported as verified positive to the employer. This is the same review step that HHS pointed to in 1997 when it found that the vast majority of low-cutoff opiate positives were being cleared as negative once an MRO looked at them. Raising the cutoff reduced how often that review had to happen in the first place, but it did not remove the review step, and it should not be skipped in any compliant program.
What this means for choosing a testing program
Employers building a testing policy should decide the opiate cutoff deliberately rather than by accident of which cup or dip card happened to be on hand. DOT-regulated safety-sensitive roles are locked into the federal 2000 ng/mL cutoff by regulation. Non-DOT employers have more flexibility, but most workplace programs benefit from mirroring the federal standard specifically because it was built to reduce dietary false positives while preserving detection of actual opioid use.
Programs that still choose a lower cutoff for clinical or monitoring reasons should plan for a higher rate of non-negative screens and make sure MRO review or an equivalent qualified review process is built into the workflow before any adverse action. A confirmed, reviewed result is a defensible result. A raw screen result is not.
Frequently asked questions
Can eating a poppy seed bagel actually cause a positive drug test?
Yes, it is possible, particularly on a more sensitive 300 ng/mL opiate panel or with a large serving close to collection time. The federal 2000 ng/mL cutoff used in most workplace programs was specifically raised in 1998 to reduce this kind of dietary false positive.
What is the difference between an OPI 300 and OPI 2000 drug test panel?
OPI 300 flags opiates at a lower concentration, 300 ng/mL, and is more likely to catch dietary poppy seed exposure along with genuine opioid use. OPI 2000 uses the federal workplace cutoff of 2000 ng/mL, designed to filter out typical poppy seed consumption while still detecting concentrations associated with opioid use.
Does a non-negative opiate screen mean an employee used heroin or abused opioids?
No. A non-negative point-of-care screen is presumptive only. It requires laboratory confirmation by GC-MS or LC-MS/MS, followed by Medical Review Officer review, before it can be reported as a verified positive. Poppy seed consumption, prescribed medication, and other legitimate causes are ruled out during that review.
Why did the federal government raise the opiate cutoff from 300 to 2000 ng/mL?
HHS raised the cutoff, effective December 1, 1998, after finding that a large share of opiate positives at the 300 ng/mL threshold were being verified as negative by Medical Review Officers, often traced to poppy seed consumption or prescribed codeine and morphine. The higher cutoff was designed to reduce that dietary noise while continuing to detect opioid use.
Compliance note: Point-of-care drug test panels are screening devices intended to produce a preliminary result. They do not diagnose drug abuse, do not identify a specific individual's history of use, and any non-negative result must be confirmed by an appropriately certified laboratory and reviewed by a qualified Medical Review Officer or equivalent process before any employment action is taken. This article is for general program-planning information and is not legal or medical advice. Employers should confirm cutoff and panel selection against their applicable DOT agency rule or company policy.
Related American Screening Corp resources
- Drug testing cups, available in multiple opiate cutoff configurations for workplace programs.
- Urine drug test dip cards for lower-volume or point-of-collection screening.
- DOT drug and alcohol testing for transportation companies, built around the federally mandated cutoffs.
- DOT pre-employment drug screen solutions.
- Workplace drug testing solutions for employers building or refreshing a testing policy.
- Laboratory and reference lab testing supplies for confirmation-stage needs.
